Literature DB >> 24910873

Escheriosome-mediated cytosolic delivery of PLK1-specific siRNA: potential in treatment of liver cancer in BALB/c mice.

Arun Chauhan, Swaleha Zubair, Ahmad Nadeem, Sajid Ali Ansari, Mohammad Yunus Ansari, Owais Mohammad.   

Abstract

AIM: In the present study, the anticancer efficacy of a novel escheriosome-based formulation of PLK1-specific siRNA was evaluated against liver cancer in BALB/c mice. MATERIALS &
METHODS: The escheriosome-based siRNA nanoparticles were prepared using lipids isolated from Escherichia coli. The escheriosomes were characterized for size, surface charge and stability. The anticancer potential of PLK1-specific siRNA formulation was ascertained on the basis of expression of pro-/anti-apoptotic factors and histopathological studies.
RESULTS: The escheriosome-entrapped siRNA was found to be released in surrounding milieu in a sustained manner. The nanoformulation was successful in modulating proapoptotic factors and eventually helped in better survival of the treated animals.
CONCLUSION: Our data demonstrate the efficacy of systemically administered siRNA in the treatment of experimental liver cancer. This novel therapeutic strategy may be applicable to a broad range of cancers in patients with the obstinate form of the disease.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24910873     DOI: 10.2217/NNM.13.21

Source DB:  PubMed          Journal:  Nanomedicine (Lond)        ISSN: 1743-5889            Impact factor:   5.307


  4 in total

Review 1.  Delivery strategies and potential targets for siRNA in major cancer types.

Authors:  So Jin Lee; Min Ju Kim; Ick Chan Kwon; Thomas M Roberts
Journal:  Adv Drug Deliv Rev       Date:  2016-05-31       Impact factor: 15.470

Review 2.  Immunotherapy for Bone and Soft Tissue Sarcomas.

Authors:  Takenori Uehara; Tomohiro Fujiwara; Ken Takeda; Toshiyuki Kunisada; Toshifumi Ozaki; Heiichiro Udono
Journal:  Biomed Res Int       Date:  2015-06-17       Impact factor: 3.411

3.  miR-451a Inhibited Cell Proliferation and Enhanced Tamoxifen Sensitive in Breast Cancer via Macrophage Migration Inhibitory Factor.

Authors:  Zhenru Liu; Tianyu Miao; Ting Feng; Zhouhua Jiang; Mingyuan Li; Liming Zhou; Hong Li
Journal:  Biomed Res Int       Date:  2015-06-16       Impact factor: 3.246

4.  Multifunctional nanosystems: growing sanguinity in siRNA therapy.

Authors:  Khan Farheen Badrealam; Mohammad Owais
Journal:  Int J Nanomedicine       Date:  2014-04-10
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.